Catalyst Dossier · compiled by CeliA 🧫
NeuroSense Therapeutics Ltd. (NRSNW)
Biotechnology · market cap —
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-01
Regulatory
Pipeline
18
programs
Upcoming events
2
next 90d+
Dossier
Not yet
generate it
The catalyst path
- 2026-12-01Regulatoryimp 5/10
- 2027-06-15 (est.)Phase 3 · Intensified protocolimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| PrimeC | Phase 2 | Amyotrophic Lateral Sclerosis |
| Paxalisib | Phase 2 | Recurrent Atypical Teratoid/Rhabdoid Tumor |
| Cerebrolysin | Phase 3 | Cadasil |
| citicoline | Phase 3 | Stroke |
| Avastin + Campto / radiotherapy + Temodal + Avastin (4 cures) | Phase 2 | Naive Unresectable Glioblastoma |
| Intensified protocol | Phase 3 | Glioblastoma |
| Chemotherapy Drug, Cancer - Physician's Choice | Phase 2 | Embryonal Tumor With Multilayered Rosettes |
| tozuleristide | Phase 3 | Pediatric Central Nervous System Tumor |
| Huperzine A | Phase 2 | Alzheimer Disease |
| Panobinostat Nanoparticle Formulation MTX110 | Phase 2 | Diffuse Intrinsic Pontine Glioma |
| Ziprasidone | Phase 3 | Affective Disorders |
| GPI 1485 | Phase 2 | Impotence |
| K27M peptide | Phase 2 | Diffuse Intrinsic Pontine Glioma |
| Binimetinib | Phase 2 | Neurofibromatosis Type 1 |
| PCV chemotherapy alone | Phase 3 | Anaplastic Gliomas With 1p/19q Codeletion |
| Fixed dose combination Ciprofloxacin/Celecoxib | Phase 2 | Amyotrophic Lateral Sclerosis |
| Cerebrolysin + donepezil | Phase 2 | Alzheimer Disease |
| Losartan | Phase 3 | Newly-diagnosed Glioblastoma |
Price & technical context
3-month
—
6-month
—
12-month
—
52-wk range
$0.05–$0.36
vs 50-day MA
—
vs 200-day MA
—
Realized vol
—
Max drawdown
-86.1%
Daily closes through 2026-09-18. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for NRSNW (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 18 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.